GRI Bio Soars 12% on Positive Phase 2a Study Results

On April 2, 2025, GRI Bio's stock price rose to 7.43 in pre-market trading, reflecting a significant increase in investor interest and confidence in the company's recent developments.

GRI Bio, Inc. has recently announced the pricing of a $5.0 million public offering, which is expected to provide the company with substantial funds to advance its innovative treatments for autoimmune diseases and boost product development. This offering is part of the company's broader strategy to secure additional funding through Series Warrants, potentially raising an extra $13.3 million.

One of the key drivers behind the recent surge in GRI Bio's stock price is the promising interim safety results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis. The study demonstrated that GRI-0621, a small molecule RAR-ß dual agonist, is safe and well-tolerated in the first 12 patients evaluated. This positive outcome has significantly boosted investor confidence in the company's pipeline and its potential to develop groundbreaking treatments for various diseases.